The Annals Visit the PharmaCE website!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

DICP, The Annals of Pharmacotherapy: Vol. 25, No. 11, pp. 1168-1170.
© 1991 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bosso, J.
Right arrow Articles by Harrison, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bosso, J.
Right arrow Articles by Harrison, G.

Research Articles

Toxicity of colistin in cystic fibrosis patients

JA Bosso, CA Liptak, DK Seilheimer, and GM Harrison

Pulmonary exacerbations of cystic fibrosis associated with strains of Pseudomonas aeruginosa that are resistant to multiple antibiotics are becoming increasingly common. The search for treatment alternatives continues and may include the reexamination of older antibiotics. Colistin sulfate is a polypeptide antibiotic with good activity against P. aeruginosa. Although its use was largely discontinued in the early 1970s because of reports of frequent renal and neurologic toxicity, intravenous colistin is often prescribed at our institution for patients with P. aeruginosa resistant to multiple-drug therapy. We prospectively monitored 19 patients during 21 courses of colistin therapy to identify the character and incidence of this agent's toxicity. Only one case of renal toxicity occurred. Six cases of neurotoxicity occurred, which were characterized by perioral paresthesia, ataxia, or both. The rate of intolerable renal adverse effects secondary to colistin therapy was appreciably lower among these patients than that reported previously for other patients. It appears that intravenous colistin can be considered for cystic fibrosis patients with strains of P. aeruginosa that are resistant to more commonly used antibiotics.


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
S. K. Kasiakou, A. Michalopoulos, E. S. Soteriades, G. Samonis, G. J. Sermaides, and M. E. Falagas
Combination Therapy with Intravenous Colistin for Management of Infections Due to Multidrug-Resistant Gram-Negative Bacteria in Patients without Cystic Fibrosis
Antimicrob. Agents Chemother., August 1, 2005; 49(8): 3136 - 3146.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. Hogardt, S. Schmoldt, M. Gotzfried, K. Adler, and J. Heesemann
Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients
J. Antimicrob. Chemother., December 1, 2004; 54(6): 1057 - 1061.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
K. H.-V. Tan, M. Mulheran, A. J. Knox, and A. R. Smyth
Aminoglycoside Prescribing and Surveillance in Cystic Fibrosis
Am. J. Respir. Crit. Care Med., March 15, 2003; 167(6): 819 - 823.
[Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
B. W. Gunderson, K. H. Ibrahim, L. B. Hovde, T. L. Fromm, M. D. Reed, and J. C. Rotschafer
Synergistic Activity of Colistin and Ceftazidime against Multiantibiotic-Resistant Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model
Antimicrob. Agents Chemother., March 1, 2003; 47(3): 905 - 909.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 1991 by Harvey Whitney Books Company.